Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GSTA1 | P08263 | 2/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11690877 | 0.92 | ESR1 (0.42) | LPAR3LPAR2LPAR1ALOX5PTGS2 | |
| SCHEMBL191427 | 0.87 | EGFR (0.38) | ALOX5PTGS2 | |
| SCHEMBL10985358 | 0.85 | CYP3A4 (0.40) | LPAR3LPAR2LPAR1ESR1 | |
| SCHEMBL10990560 | 0.82 | DHFR (0.37) | — | |
| SCHEMBL10982120 | 0.82 | ALOX5 (0.42) | ALOX5PTGS2ENPP2 | |
| SCHEMBL7157597 | 0.82 | CYP3A4 (0.37) | LPAR3LPAR2LPAR1ALOX5PTGS2 | |
| SCHEMBL5415808 | 0.80 | HMGCR (0.48) | LPAR3LPAR2LPAR1ESR1AKR1C4 | |
| SCHEMBL11154052 | 0.80 | HMGCR (0.48) | LPAR3LPAR2LPAR1ESR1AKR1C4 | |
| SCHEMBL21359725 | 0.80 | HMGCR (0.48) | LPAR3LPAR2LPAR1ESR1AKR1C4 | |
| SCHEMBL5410693 | 0.80 | HMGCR (0.48) | LPAR3LPAR2LPAR1ESR1AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442735-B2 | Nucleating agent composition and crystalline polymer compositions containing the same | ASAHI DENKA CO., LTD. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20070054996-A1 | Nucleating agent composition and crystalline polymer compositions containing the same | ASAHI DENKA CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054996-A1 | Nucleating agent composition and crystalline polymer compositions containing the same | NAF1, RCC1, RAN | LPAR3 305/4885LPAR2 328/4885LPAR1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.